Medicare Enrolled
Dr. Jochen Lorch, M.D.
Hematology & Oncology · Chicago, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lorch from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lorch?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lorch
Dr. Jochen Lorch is a hematology & oncology specialist in Chicago, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lorch performed 46,270 Medicare services across 1,275 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lorch received a total of $32,560 from 13 pharmaceutical and/or device companies across 43 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lorch is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 21% volume in IL
$32,560 industry payments
Medicare Practice Summary
Medicare Utilization ↗46,270
Medicare services
Top 21% in IL for hematology & oncology
1,275
Unique beneficiaries
$22
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,314 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
8,250 | $1 | $5 |
| Nivolumab injection (Opdivo) | 7,760 | $24 | $97 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
6,120 | $38 | $170 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
5,400 | $0 | $7 |
| Immune globulin infusion (Gammagard) An injection of immune globulin (Gammagard Liquid) to provide antibodies. The dose specified is 500 mg. |
5,180 | $36 | $134 |
| Pembrolizumab injection (Keytruda) | 4,400 | $43 | $171 |
| Denosumab injection (Prolia/Xgeva) | 2,520 | $18 | $58 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,419 | $21 | $244 |
| Bortezomib injection, 0.1 mg Administration of a 0.1 mg dose of bortezomib medication via injection. |
1,089 | $3 | $174 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
668 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 500 | $1 | $76 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
432 | $4 | $10 |
| Injection, granisetron hydrochloride, 100 mcg | 320 | $0 | $5 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
264 | $75 | $821 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
219 | $108 | $940 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
200 | $13 | $143 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
187 | $143 | $434 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
179 | $17 | $129 |
| Cyclophosphamide, 100 mg | 151 | $15 | $111 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
131 | $101 | $323 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
120 | $53 | $410 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
120 | $24 | $203 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
116 | $1 | $3 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
91 | $2 | $94 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
70 | $60 | $326 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
67 | $12 | $88 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
64 | $23 | $215 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
38 | $54 | $464 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
33 | $46 | $393 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
30 | $1 | $4 |
| Flexible laryngoscopy A diagnostic exam of the voice box using a flexible endoscope to visualize the larynx. |
24 | $105 | $611 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
24 | $1 | $8 |
| New patient office visit, complex (60-74 min) | 23 | $177 | $625 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
17 | $8 | $20 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
17 | $15 | $109 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
14 | $98 | $250 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
13 | $25 | $338 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.5% high complexity
68.3% medium
1.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$32,560
Total received (2018-2024)
Avg $5,427/year across 6 years
Top 16% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
13
Companies
43
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$25,002 (76.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$6,299 (19.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,259 (3.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$11,438
2023
$1,627
2022
$2,854
2020
$1,000
2019
$5,341
2018
$10,300
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$7,102
Coherus Biosciences Inc.
$2,177
Eisai Inc.
$2,159
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Bayer HealthCare Pharmaceuticals Inc.
$7,960
Novartis Pharmaceuticals Corporation
$7,102
Eisai Inc.
$6,728
Exelixis Inc.
$4,122
Genentech USA, Inc.
$3,211
Coherus Biosciences Inc.
$2,298
EISAI INC.
$900
SK Life Science, Inc.
$105
Regeneron Healthcare Solutions, Inc.
$50
Seagen Inc.
$25
MorphoSys, US Inc.
$23
Merck Sharp & Dohme LLC
$20
AstraZeneca Pharmaceuticals LP
$15
Top 3 companies account for 66.9% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · CABOMETYX · Cabometyx · KEYTRUDA · LIBTAYO · LOQTORZI · Lenvima · MEKINIST · MONJUVI · Non-Covered · Non-Covered Product · Udenyca · Vitrakvi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (77%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
326
Per 100K population
6.3
County median income
$81,797
Nearest hospital
NORTHWESTERN MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lorch is a mixed practice specialist, with above-average Medicare volume (top 21% in IL), with consulting-driven industry engagement in the top 16% of IL peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lorch experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Lorch performed 8,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lorch receive payments from pharmaceutical companies?
Yes. Dr. Lorch received a total of $32,560 from 13 companies across 43 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lorch's costs compare to other hematology & oncology specialists in Chicago?
Dr. Lorch's average Medicare payment per service is $22. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lorch) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Chicago
Browse hematology & oncology specialists in Chicago ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Eisai Inc. Payments to Doctors
See all physicians who received payments from Eisai Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology